Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia

Phase 4

Completed

Conditions: Lymphoma

Interventions: Drug: RASBURICASE SR29142

First Posted Date: 2020-04-16

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 50

Registration Number: NCT04349306

Locations: 🇨🇳
investigational site CHINA, China, China

Hydroxychloroquine in Outpatient Adults With COVID-19

Phase 1

Terminated

Conditions: Coronavirus Infection

Interventions: Drug: Placebo
Drug: Hydroxychloroquine SAR321068

First Posted Date: 2020-04-03

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 8

Registration Number: NCT04333654

Locations: 🇺🇸
Investigational Site Number 8400001, Boston, Massachusetts, United States
🇧🇪
Investigational Site Number 0561002, Lodelinsart, Belgium
🇫🇷
Investigational Site Number 2501001, Bordeaux Cedex, France

and more 4 locations

Sarilumab COVID-19

Phase 3

Completed

Conditions: Corona Virus Infection

Interventions: Drug: Sarilumab SAR153191
Drug: Placebo

First Posted Date: 2020-03-31

Last Posted Date: 2022-03-17

Lead Sponsor: Sanofi

Target Recruit Count: 420

Registration Number: NCT04327388

Locations: 🇦🇷
Investigational Site Number 0320003, Caba, Argentina
🇨🇱
Investigational Site Number 1520001, Talca, Chile
🇨🇦
Investigational Site Number 1240002, Toronto, Canada

and more 44 locations

Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation

Phase 1

Terminated

Conditions: Immune System Disorder

Interventions: Drug: Isatuximab SAR650984
Drug: Acetaminophen (paracetamol) or equivalent
Drug: Ranitidine or equivalent
Drug: Diphenhydramine or equivalent
Drug: Methylprednisolone or equivalent
Drug: Montelukast or equivalent

First Posted Date: 2020-03-04

Last Posted Date: 2023-06-27

Lead Sponsor: Sanofi

Target Recruit Count: 23

Registration Number: NCT04294459

Locations: 🇺🇸
Investigational Site Number :8400004, Houston, Texas, United States
🇺🇸
Investigational Site Number :8400002, New York, New York, United States
🇺🇸
Investigational Site Number :8400001, Rochester, Minnesota, United States

and more 3 locations

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: Isatuximab SAR650984
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Montelukast or equivalent
Drug: Acetaminophen
Drug: Diphenhydramine or equivalent
Drug: Methylprednisolone or equivalent

First Posted Date: 2020-02-17

Last Posted Date: 2024-10-31

Lead Sponsor: Sanofi

Target Recruit Count: 337

Registration Number: NCT04270409

Locations: 🇦🇺
Investigational Site Number :0360008, Liverpool, New South Wales, Australia
🇯🇵
Investigational Site Number :3920001, Shibuya-ku, Tokyo, Japan
🇱🇹
Investigational Site Number :4400001, Vilnius, Lithuania

and more 102 locations

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)

Phase 3

Completed

Conditions: Neurodermatitis

Interventions: Drug: Placebo
Drug: Dupilumab SAR231893
Drug: Moisturizers
Drug: Low to medium potent topical corticosteroids
Drug: Topical calcineurin inhibitors

First Posted Date: 2019-12-17

Last Posted Date: 2022-12-21

Lead Sponsor: Sanofi

Target Recruit Count: 160

Registration Number: NCT04202679

Locations: 🇨🇦
Investigational Site Number :1240006, Surrey, British Columbia, Canada
🇨🇱
Investigational Site Number :1520006, Osorno, Reg Metropolitana De Santiago, Chile
🇭🇺
Investigational Site Number :3480005, Pécs, Hungary

and more 54 locations

Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Amcenestrant (SAR439859)
Drug: Letrozole

First Posted Date: 2019-12-09

Last Posted Date: 2022-06-29

Lead Sponsor: Sanofi

Target Recruit Count: 105

Registration Number: NCT04191382

Locations: 🇺🇸
Investigational Site Number 8400010, Los Angeles, California, United States
🇺🇸
Investigational Site Number 8400005, Lincoln, Nebraska, United States
🇺🇸
Investigational Site Number 8400012, Tacoma, Washington, United States

and more 29 locations

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

Phase 3

Completed

Conditions: Neurodermatitis

Interventions: Drug: Dupilumab SAR231893
Drug: Placebo
Drug: Moisturizers
Drug: Low to medium potent topical corticosteroids
Drug: Topical calcineurin inhibitors

First Posted Date: 2019-12-03

Last Posted Date: 2022-12-12

Lead Sponsor: Sanofi

Target Recruit Count: 151

Registration Number: NCT04183335

Locations: 🇺🇸
Investigational Site Number :8400001, Dublin, Ohio, United States
🇺🇸
Investigational Site Number :8400025, Houston, Texas, United States
🇺🇸
Investigational Site Number :8400011, Gilbert, Arizona, United States

and more 60 locations

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

Phase 3

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: Placebo
Drug: Dupilumab SAR231893
Drug: non sedating H1-antihistamine

First Posted Date: 2019-11-27

Last Posted Date: 2024-12-11

Lead Sponsor: Sanofi

Target Recruit Count: 397

Registration Number: NCT04180488

Locations: 🇺🇸
Allergy & Asthma Specialists, PSC Site Number : 8400020, Owensboro, Kentucky, United States
🇺🇸
Johns Hopkins University (Asthma and Allergy Center) Site Number : 8400016, Baltimore, Maryland, United States
🇺🇸
Allergy and Clinical Immunology Associates Site Number : 8400024, Pittsburgh, Pennsylvania, United States

and more 98 locations

Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: SAR442168

First Posted Date: 2019-11-20

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 6

Registration Number: NCT04171310

Locations: 🇬🇧
Investigational Site Number 8260001, Nottingham, United Kingdom

Home Terms & Conditions Privacy Policy